Plants produce recombinant apolipoprotein AI on a commercial level(07/16/2007) Canadian SemBioSys achieves critical milestone SemBioSys Genetics Inc. has successfully developed commercial levels of apolipoprotein AI and its variant apolipoprotein AI (Milano) (collectively referred to as Apo AI) in safflower seed lines. Apo AI is believed by many clinicians to be the basis ...
SemBioSys achieves major insulin milestone(07/20/2006) Canadian Biotechnology Company achieves commercially viable level of insulin in safflower SemBioSys Genetics Inc. has achieved its commercial target levels of human insulin (insulin) accumulation in safflower with 1.2 percent of total seed protein. The results from the Company's commercial plant system exceeded its target of one percent ...
SemBioSys obtains rights to platform-enhancing technologies from Syngenta(06/19/2006) Canadian Biotechnology Company to expedite development process for biopharmaceuticals SemBioSys Genetics Inc., a biotechnology company developing a pipeline of protein-based pharmaceuticals and non-pharmaceutical products, announced an agreement to acquire technology assets and in-license intellectual property related to the ...
Top
